![](https://investorshub.advfn.com/uicon/602751.png?cb=1523775966)
Sunday, August 06, 2017 3:52:41 PM
http://www.biopharmadive.com/news/jj-drops-stem-cell-partner-capricor/446688/
This is particularly interesting: Capricor is changing the indication for their drug (stem cells).
"...Capricor is now pursuing CAP-1002 as a treatment for Duchenne muscular dystrophy."
Why did they give up on treating CHF?
Meanwhile, I believe Mesoblast is still looking for a new partner to help fund their 100 million dollar trials.
Of the three: USRM, Mesoblast, and Capricor, who had the best results from their trails for treating CHF?
What does this say about USRM's competition?
Could J&J be looking at USRM?
My one post for the day..:)
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM